Skip to main content

New systems of controlled gene expression for improved delivery of therapeutic substances

Objective

This proposal wishes to contribute to the development of new treatments against high frequency diseases that are cancers, retinopathies and arteriosclerosis, touching up to 42% of the population. The proposed approach is to create new gene transfer systems based on programs of coupled transcriptional and post-transcriptional regulations of gene expression, for an efficient and controlled delivery of active therapeutic agents. Regulatory tools emerging from fundamental research results will allow the creation of new vectors and genetically modified cells efficiently expressing combinations of antiangiogenic agents or growth factors and cytokines. Antiangiogenesis can target up to 100% of solid tumours and most retinopathies. Antigenic and anti-inflammatory agents target thermo plaque, to prevent myocardial infarction. The vectors and cell lines delivering therapeutic substances, tested on animals models, will be commercialised to big industrial companies in Europe that think launching clinical assays and exploit them in a large scale. This program is expected to create a large added value for European community.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Address
Avenue Jean Poulhès
31403 Toulouse
France

Participants (5)

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
France
Address
Avenue Président Léon Bernard 2 Faculté De Medecin
35043 Rennes
CISTRONICS CELL TECHNOLOGY GMBH
Switzerland
Address
Einsteinstrasse 1-5
8093 Zurich
MILLEGEN SARL
France
Address
10, Avenue De L'europe
31525 Ramonville St.agne
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
Address
80,Tennis Court Road, 80
CB2 1GA Cambridge
UNIVERSITE LIBRE DE BRUXELLES
Belgium
Address
50,Rue Des Prof. Jeener Et Brachet 12
6041 Gosselies